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Abstract
The neurochemical effects of partial D2-like agonist

(i.e., terguride) to alter striatal DOPA accumulation

under high and low dopaminergic tone was examined in

preweanling rats.

To this end, they were injected with

reserpine or GBL to create a state of low dopaminergic

tone and saline was used to create a state of high
dopaminergic tone.
In Experiment 1, preweanling rats were treated either
repeatedly or acutely with reserpine or saline.

The rats

in the repeated condition received daily reserpine
injections from PD 16 - PD 20, and rats in the acute

condition only received reserpine treatment on PD 20.

On

PD 21, all rats were injected with the full D2-like

antagonist haloperidol, the partial D2-like agonist
terguride, the full D2-like agonist quinpirole, or saline.
They were then injected with NSD 1015 and striatal DOPA
accumulation was measured.

As expected, the results

showed that both terguride and quinpirole reduced striatal

DOPA accumulation during a state of low dopaminergic tone.
During a state of high dopaminergic tone, terguride had
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similar effects as haloperidol, increasing in DOPA

accumulation.

In Experiments 2 and 3, terguride's ability to

modulate dopamine synthesis under states of low or high
dopaminergic tone was assessed using impulse flow

inhibitor y-butyrolactone (GBL) or saline, respectively.
Preweanling rats were injected with haloperidol,
quinpirole, terguride, or saline on PD 21.

After the drug

injections, they were injected with GBL followed by NSD
1015.

The results showed that(terguride, like quinpirole,

partially inhibited the GBL-induced increase in striatal
DOPA accumulation.

On the other hand, terguride had a

haloperidol-like effect under a state of high dopaminergic

tone.

When considered together, the results from all

three experiments indicate that terguride have agonist

like (quinpirole-like) effects under a low dopaminergic

tone and antagonist-like (haloperidol-like) effects under
a high dopaminergic tone during preweanling period.
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CHAPTER ONE
OVERVIEW

General Overview
In the United States, many people are under going
rehabilitation for psychostimulant (e.g., cocaine,

amphetamine, and methamphetamine) addiction (National

Institute on Drug Abuse, 1999).

Most people seek

psychostimulant drugs for their reinforcing effects.

When

these types of drugs are taken qver a long period of time,
drug abusers will go through a withdrawal phase when the
drugs are not present.

Common symptoms of psychostimulant

withdrawal are psychomotor retardation, depression,

fatigue, and decreased motivation for natural reward (e.g.,
food seeking behavior)(Orsini, Koob, &'Pulvirenti, 2001).

In animal models, withdrawal symptoms are usually measured
by observing psychomotor retardation after long exposure

to psychostimulant drugs (Pulvirenti & Koob, 1994) .
According to Pulvirenti and Koob (1994), drug

withdrawal is due to a reduction in dopamine
neurotransmission, which is caused by increased

sensitivity of D2-like autoreceptors.
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Recently, partial

D2-like agonists

(e.g., aripiprazole, preclamol,

terguride,

SDZ 208-911, and SDZ 208-912) have received much attention
as potential pharmacotherapies because of their unique

property of "normalizing" dopamine neurotransmission
(Pulvirenti, Balducci, Piercy, & Koob, 1998) .

Specifically, partial D2-like agonists act as either

agonists or antagonists depending on intrinsic

dopaminergic activity (for a review, see Clark, Hjorth, &

Carlsson, 1985).

Thus, partial D2-like agonists act as

antagonists when the dopamine system is stimulated, but

act as agonists when the dopamine system is depressed.
For these reasons, partial D2-like agonists should block

the rewarding effects of psychostimulants while at the
same time maintaining normal dopamine tone.

The latter

effect could potentially alleviate drug withdrawal and
craving.
The antagonistic effects of partial D2-like agonists
have been amply shown in animal studies.

For example,

cocaine or amphetamine self-administration is

significantly reduced when partial D2-like agonists are

given to rodents and monkeys (Callahan & Cunningham, 1993;
Pulvirenti, Smith, & Koob, 1994).
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It has also been

demonstrated that partial D2-like agonists reduce

amphetamine-induced stereotyped behavior and locomotor

activity (Clark, Furmidge, Petry, Tong, Ericsson, &

Johnson, 1991).

Thus, partial D2-like agonists behave as

dopamine antagonists when co-administered with indirect
dopamine agonists such as amphetamine and cocaine

(Pulvirenti & Koob, 1994).

Interestingly, partial D2-like agonists have

agonistic effects when dopamine neurotransmission is
depressed.

For example, Orsini et al.

(2001) demonstrated

that terguride was able to increase saccharin-reinforced

responding in dopamine-depleted ,rats.

Normally, rats

going through amphetamine withdrawal (i.e., a state of low
!■
dopaminergic tone) exhibit suppressed responding for a

natural reward (e.g., saccharin)1.
I

However, terguride

increases responding for saccharin in a state of low

dopaminergic tone, suggesting that this partial D2-like

agonist was exhibiting agonistic properties.

Therefore,

while the majority of behavioral studies have shown that
partial D2-like agonists exhibit antagonistic properties

(Callahan & Cunningham, 1993; Clark et al., 1991;
Pulvirenti & Koob, 1994; Pulvirenti et al., 1994),
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accumulating evidence suggests that partial D2-like
agonists exhibit agonistic effects on behavior in a state

of low dopaminergic tone (Orsini et al., 2001).

In summary, partial D2-like agonists may serve as
novel pharmacotherapies for psychostimulant addiction.

To

date, most studies examining partial D2-like agonists have

used adult animals, while relatively few studies have
examined the effects of partial D2-like agonists during

early ontogeny.

This thesis is designed to further

investigate the properties of partial' D2-like agonists in

the developing brain.

4

CHAPTER TWO
DOPAMINE RECEPTORS

Dichotomy Based on Receptor Subtypes
There are five different types of dopamine receptors:

Di, D2, D3, D4 and D5.

Due to functional and

pharmacological differences, these receptor subtypes are
divided into two families: Dl-like and D2-like receptors.

Dl-like receptors consist of D± and D5 receptors, while DRlike receptors include D2, D3, and D4 receptors (Seeman &

Van Tol, 1994; Sokoloff, Giros, Martres, Bouthenet, &
Schwartz, 1990; Sunahara, Seeman, Van Tol, & Niznik, 1993)

Dl-like receptors stimulate adenylyl cyclase activity
(Dearry, Gingrich, Falardeau, Fremeau, Bates, & Caron,

1990; Monsma, Mahan, McVittie, Gerfen, & Sibley, 1990),
while D2-like receptors inhibit adenylyl cyclase activity

(Chio, Drong, Riley, Gill, Slightom, & Huff, 1994;

Robinson & Caron, 1996).

The mechanisms responsible for

these effects are known, because stimulation of Dl-like

receptors activates a Gs-protein and increases adenylyl
cyclase activity; whereas, stimulation of D2-like
receptors activates a Gi-protein and inhibits adenylyl
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cyclase activity (Cooper, Bloom, & Roth, 2003) .
Alterations of adenylyl cyclase activity modulate cyclic

adenosine monophosphate (cAMP) formation and protein
kinase A activity (Cooper et al., 2003) .

Another

difference between Dl-like and D2-like receptors is the
Dl-like receptors do not have

presence of introns.

introns in their coding sequence, whereas D2-like

receptors are interrupted by introns (Civelli, Bunzow, &
Grandy, 1993; Gingrich & Caron, 1993; O'Dowd, 1993) .

Dl-Like Receptors
As mentioned above, Dl-like receptors consist of the
Di and D5 subtypes.

The Dx receptor subtype is the most

widespread dopamine receptor (Dearry et al., 1990),
because it is found throughout various brain regions,

including the striatum, nucleus accumbens, olfactory

tubercles, hypothalamus, thalamus, hippocampus, and
amygdala (Fremeau, Duncan, Fornaretto, Dearry, Gingrich,
Breese, & Caron, 1991; Weiner, Levey, Sunahara, Niznik,

O'Dowd & Brann, 1991) .

The Dx receptor has been implicated

in unlearned behaviors (Arnt, 1987; Clark & White, 1987),
psychostimulant reward (Di Chiara, 1995), cognition

(Williams & Goldman-Rakic, 1995)-, and incentive responding
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under food deprivation (Di Chiara, Tanda, Cadoni, Acquas,

Bassareo, & Carboni, 1998; Miller, Wickens, & Beninger,
1990) .

The D5 receptor subtype has a function that is very
similar to the Dx receptor.

For example, the D5 receptor

plays an important role in reward processes and incentive

motivation (for a review, see'Emilien, Maloteaux, Geurts,

Hoogenberg, & Cragg, 1999).

D5 receptors are predominately

located in forebrain regions.

More specifically, D:5

receptors are found in cerebral cortex, lateral and medial

thalamus, striatum, substantia nigra, medial thalamus and
hippocampus (Chio, Lajiness, & Huff, 1994; Huntley,'

Morrison, Prikhozhan, & Sealfon, 1992; Rappaport, Sealfon,
Prikhozhan, Huntley, & Morrison,' 1993) .

D2-Like Receptors
D2-like receptors mediate- motor movement

(Arnt, 1987),

reward mechanisms (Emilien et al., 1999) and they have

also been implicated in schizophrenia- (Arinami, Gao,
Hamaguchi, & Toru, 1997) and substance abuse (Blum, Noble,

Sheridan, Montgomery, Ritchie, Jagadeeswaran, Nogami,
Briggs, & Cohn, 1990.) .

For example, D2-receptor deficient

mice show reduced locomotion, rearing, coordinated
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The D3 and D4 receptor subtypes are involved in motor

movement and neuropsychiatric disorders in both humans and
animals

(Accili, Fishburn, Drago, Steiner, Lachowicz, Park

Gauda, Lee, Cool, Sibley, Gerfen, Westphal, & Fuchs, 1996;

Ekman, Nissbrandt, Heilig, Dijkstra, & Eriksson, 1998;
Suzuki, Mihara, Kondo, Tanaka, Nagashima, Otani, & Kaneko,

2000; Wong, Buckle, & Van Tol, 2000) . Interestingly, the D3

receptor subtype has been implicated in the hyperactivity
associated with attention-deficit hyperactivity disorder

(ADHD)

(Barr, Wigg, Wu, Zai, Bloom, Tannock, Roberts,

Malone, Schachar, & Kennedy, 2000).

In addition, many

researchers believe that there is a strong relationship

between the D4 receptor and novelty seeking behavior
(Benjamin, Li, Patterson, Greenberg, Murphy, & Hamer, 1996

Benjamin, Osher, Kotler, Nemanov, Belmaker, & Ebstein,
2000; Ebstein, Novick, Umansky, Priel, Osher, Blaine,
Bennett, Nemanov, Katz, & Belmaker, 1996; Ebstein, Nemanov

Klotz, Gritsenko, & Belmaker, 1997; Okuyama, Ishiguro,
Nankai, Shibuya, Watanabe, & Arinami, 2000; Strobel, Wehr,
Michel, & Brooke, 1999; Tomitaka, Tomitaka, Otuka, Kim,
Matuki, Sakamoto, & Tanaka, 1999). For example, D4 knock

out mice show significantly less novelty seeking behavior
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than controls (Dulawa, Grandy, Low, Paulus, & Geyer, 1999).

The D3 receptor subtype is found mostly in the nucleus
accumbens and island of Calleja (MeadOr-Woodruff, Damask,

& Watson, 1994), while the D4 receptor subtype is found in
the cortex, hippocampus, ventral striatum, globus pallidus,
substantia nigra, thalamus, and ventral hypothalamus (for
a review, see Callier, Snapyan, Le Crom, Prou, Vincent, &

Vernier, 2 003) .

Dichotomy Based on Neuroanatomical Location

Postsynaptic Receptors
Postsynaptic receptors are typically stimulated by
neurotransmitter released from nerve terminals.

After

dopamine binds to postsynaptic receptors, second messenger
systems are either stimulated or inhibited.

Second

messenger activity is modulated via protein

phosphorylation, which regulates many factors including:

cAMP, adenylyl cyclase, voltage- and calcium-dependent
channels, protein kinases, and neurotransmitter release
(Cooper et al., 2003).

Typically, the end result of these

actions is that an excitatory or inhibitory postsynaptic

potential is initiated in the dendrites.
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Presynaptic Receptors: Autoreceptors
D2-like autoreceptors are located presynaptically and

are sensitive to the same neurotransmitter that is
released from the terminal (Cooper et al. , 2003) .

In

other words, dopamine neurons have specialized receptors,
called autoreceptors that are sensitive to the

neurotransmitter released by the neuron itself.
Conceptually, dopamine autoreceptors play an important
role in self-regulation. Activating these autoreceptors

inhibits dopamine transmission by decreasing dopamine

release, firing rate, and tyrosine hydroxylase activity
(Cooper et al., 2003).

In general, dopamine receptor

agonists decrease dopamine synthesis by stimulating

autoreceptors, whereas dopamine receptor antagonists
increase dopamine synthesis by blocking autoreceptors.

The distinction between autoreceptors and
postsynaptic receptors involves more than just location
and function.

When compared to.postsynaptic D2-like

receptors, D2-like autoreceptors have a higher affinity for
dopamine and certain dopamine receptor.agonists (Cooper et

al., 2003) .

Thus, D2-like autoreceptors are selectively

activated after administration of a partial D2-like
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agonist (Meller, Bohmaker, Namba, Friedhoff, & Goldstein,
1987).

I
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CHAPTER THREE
DOPAMINE METABOLISM

Dopamine Synthesis
Dopamine is a catecholamine neurotransmitter found

predominately in the central nervous system.

Dopamine is

synthesized from the amino acid precursor tyrosine, which

is converted in the cytoplasm to L-3,4dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase.

In the cytoplasm, DOPA decarboxylase transforms L-DOPA to
dopamine (see Figure 1) (Cooper et al., 2003) .

Tyrosine

hydroxylase is the rate-limiting step in this biosynthetic
pathway.
The main regulatory factors modulating dopamine

synthesis are the firing rate of the neurons, end-product

inhibition, and autoreceptors located in the nerve-endings
(Cooper et al., 2003). In general, stimulation of

somatodendritic autoreceptors inhibits the firing rate of
the neurons via a negative feedback mechanism (for a

review, see Roth & Elsworth, 1995).

On the other hand,

antagonizing these autoreceptors increases the firing rate

and, thus, disinhibits the release and synthesis of

13

Tyrosine
Tyrosine
Hydroxylase

L-DOPA
DOPA
Decarboxylase
▼

Dopamine

Figure 1.
Simplified presentation of the synthesis of
dopamine metabolism. L-DOPA = L-3,4dihydroxyphenylalanine.
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neurotransmitter (Roth & Elsworth, 1995) .

End-product

inhibition is primarily controlled by pteridine activity.

Specifically, when dopamine builds up in the

cytoplasm, it decreases the release of pteridine (a co
factor for tyrosine hydroxylase).

The reduced amount of

pteridine decreases tyrosine hydroxylase activity and
causes a corresponding decline in dopamine synthesis
(Cooper et al., 2003).

Autoreceptors are present at the soma, dendrites, and

nerve terminals.

Stimulating autoreceptors on the nerve

terminals inhibits dopamine synthesis by reducing the
amount of pteridine.

As mentioned above, pteridine

modulates the activity of tyrosine hydroxylase.

Thus,

decreased pteridine causes a reduction in tyrosine

hydroxylase activity and a corresponding decrease in
dopamine synthesis and release.

In contrast, stimulating

autoreceptors on the soma and dendrites (somatodendritic
autoreceptors) slows the firing rate of dopamine neurons

through a negative feedback mechanism.

Both

somatodendritic and nerve terminal autoreceptors combine

to provide feedback modulation of dopaminergic
transmission (Cooper et al., 2003).
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Termination of Dopamine Transmission
Dopaminergic transmission is primarily terminated by
uptake of the released neurotransmitter back into the axon

terminal.

The dopamine transporter is responsible for

this reuptake action (Cooper et al., 2003) .

The dopamine

transporter is found only in dopamine neurons, thus it is

a unique marker for dopaminergic neurons (Kuhar, 1998).
Dopamine is catabolized by the actions of two enzymes

Monoamine oxidase (MAO) and catechol-O-methyltransferase
(COMT) (see Figure 2)

(Cooper et al., 2003) .

MAO, which is

found in the mitochondrial membranes of neurons and glial

cells, transforms dopamine to a corresponding aldehyde
(Cooper et al., 2003).

More specifically, when MAO

oxidizes dopamine, dihydroxyphenylacetaldehyde (DOPAL) is
produced.

DOPAL is subsequently metabolized by aldehyde

dehydrogenase into 3,4-dihydroxyphenylacetic acid (DOPAC).
DOPAC then diffuses out of the cell and is transformed

into homovanillic acid (HVA) by COMT (Cooper et al. , 2003)

16

Figure 2. Metabolism of dopamine in the dopaminergic
nerve terminal and synapse. MAO = monoamine oxidase,
DOPAL = dihydroxyphenylacetaldehyde, AD = aldehyde
dehydrogenase, DOPAC = 3,4-dihydroxyphenylacetic acid,
COMT = catechol-O-methyltransferase, HVA = homovanillic
acid.
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CHAPTER FOUR
EFFECTS OF DOPAMINE AGONISTS AND ANTAGONISTS

Systemic Administration of Dopamine Agonists and
Antagonists in Adult Rats
Non-selective dopamine receptor agonists (e.g.,

R(-)-propylnorapomorphine (NPA) or apomorphine) bind to
pre- and postsynaptic D2-like receptors as well as

postsynaptic Dl-like receptors (for a review, see Arnt,
1987).

When these drugs are systemically injected, adult

animals exhibit dose-dependent increases in locomotor
activity, rearing, grooming, sniffing, and oral behaviors

(Harkin, Kelly, Frawley, O'Donnell, & Leonard, 1999;
I
Havemann, Magnus, Moller, & Kuschinsky, 1986; Meller,

Bordi & Bohmaker, 1988).

Apomorphine also causes a dose-

dependent increase in straub tail behavior (i.e., the tail
forms an angle of at least 30°)
Shafaghi, 1992).

(Zarrindast, Bayat, &

Depending on receptor occupancy, a

continuum of behaviors can be observed.

Lower doses of

non-selective dopamine agonists cause non-stereotyped

behaviors (e.g., grooming, locomotor activity, and
rearing), while higher doses cause more intense
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stereotyped behaviors (patterned locomotor activity,
sniffing, and oral behaviors).

Selective stimulation of the dopamine receptor
subtypes produces characteristic behavioral patterns.

For

example, selective stimulation of Dl-like receptors with

SKF 38393 causes increased grooming, non-stereotyped
sniffing, rearing, and locomotor activity (Giorgi,

DeMontis, Porceddu, Mele, Calderini, Toffano, & Biggio,
1987; Meller et al., 1988; Molloy & Waddington, 1984).

On

the other hand, more intense behaviors are observed when

D2-like agonists (i.e., quinpirole and bromocriptine) are

administered.

Animals show increased head shakes

(Gonzalez-Lima, Stiehl, & Medina, 1984), locomotor

activity (Arnt & Hyttel, 1990), straub tail behavior

(Zarrindast et al., 1992), sniffing, and oral behavior
(Meller et al., 1988).

These agonist-elicited behaviors

are blocked by dopamine antagonists.

For example, SKF

38393-induced grooming behavior is attenuated by SCH 23390

(a Dl-like antagonist), while NPA-induced locomotor

activity, rearing, and sniffing behaviors are attenuated
by sulpiride (a D2- like antagonist)

White, 1987).
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(Arnt, 1987; Clark &

Central Administration of Dopamine Agonists and
Antagonists in Adult Rats

Microinjecting selective or non-selective Dl-like or

D2-like agonists elicit different responses depending on
brain area and dosage of injection.

For example,

injecting a non-selective dopamine receptor agonist (NPA)
into the dorsal striatum elicits stereotyped behaviors

(Bordi, Carr, & Meller, 1989).

More specifically, dose-

dependent increases in the intensity and duration of
sniffing and oral stereotypies were observed after

injecting NPA into sub-regions of the dorsal striatum.
Higher doses of NPA created more intense and longer

durations of these stereotypical behaviors (Bordi et al.,
1989) .
On the other hand, biphasic drug effects are observed

when the selective D2-like agonist quinpirole is injected
into the dorsal striatum.

For example, rats showed

increased locomotor activity when a high dose of
quinpirole was bilaterally injected into the dorsal

striatum; however, rats showed decreased locomotor
activity when a low dose of quinpirole was microinjected
into the same region (Van Hartesveldt, Cottrell, Potter, &

Meyer, 1992).

In a similar experiment, microinjecting
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quinpirole into the dorsal striatum caused a dosedependent decrease in locomotor and rearing behavior
(Canales & Iversen, 1998; Swanson, Heath, Stratford, &

Kelley, 1997), while causing an increase in stereotyped
behavior (Canales & Iversen, 1998).

In addition,

microinjecting quinpirole into the dorsal striatum
increased yawning (Canales & Iversen, 1998).
Surprisingly, very different effects were found when
centrally administering the Dl-like agonist SKF 38393 into

the dorsal striatum.

Specifically, when SKF 38393 was

microinjected into the dorsal striatum, there were no
observable changes in behavior (i.e., locomotor activity

and stereotypy).

However, after 3-4 hr, rats exhibited a

decrease in "still" behavior, as well as an increase in

oral behavior (Delfs & Kelley, 1990).

Injecting non-selective and selective agonists into
the ventral striatum (i.e., nucleus accumbens) caused a
different pattern of results.

When the non-selective

dopamine agonist, apomorphine, was injected into the
ventral striatum, it caused a dose-dependent reduction in
locomotor activity.

More specifically, when a low dose of

apomorphine (1 - 1000 ng) was microinjected into the
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ventral striatum, there was no change in locomotor

activity; however, a higher dose of apomorphine (10 jig)
caused a significant decrease in locomotor activity (Barik
& de Beaurepaire, 1996).

Likewise, when quinpirole was

microinjected into the ventral striatum, a reduction of
both locomotor activity and rearing was observed, however
stereotyped behaviors became more prominent (Canales &
Iversen, 1998) .

Different patterns of effects are observed when

selective Dl-like agonists are microinjected into the
ventral striatum.

Direct Dl-like agonists (SKF 38393 or

SKF 82958) cause significant dose-dependent increases in

locomotor activity and rearing (Swanson et al., 1997) .

Systemic Administration of Dopamine Agonists and
Antagonists in Preweanling Rats
When non-selective dopamine receptor agonists (e.g.,

NPA or apomorphine) are systemically given to young rats

they exhibit very similar behavioral effects as adults,
including increased grooming, locomotor activity,

sniffing,

and intense stereotypies (McDougall & Bolanos, 1994;

Mestlin & McDougall, 1992; Shalaby & Spear, 1980).

More

specifically, apomorphine increased locomotor activity at
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all ages tested (PD 7, PD 14, PD 21, PD'28, and PD 35),
but stereotyped sniffing was not observed until PD 21

(Shalaby & Spear, 1980) .

Similar effects were found using

NPA, as this non-selective dopamine receptor agonist

increased locomotor activity at PD 17 and stereotyped

sniffing at both PD 11 and PD 17 (McDougall & Bolanos,
1994) .
When selective dopamine Dl-like or D2-like agonists

are given, young rats again show behavioral patterns

similar to adults (McDougall, Arnold, & Nonneman, 1990) .

For example, 11- and 17-day-old rats showed increased

locomotor’activity and grooming after being treated with
SKF 38393

(a Dl-like agonist)

(McDougall et al., 1990).

In addition, the D2-like agonist quinpirole increased
locomotor activity in preweanling rats, an effect that was
antagonized by either SCH 23390 (a Dl-like antagonist) or

sulpiride (a D2-like antagonist).
Interestingly, some dose-dependent effects are
observed across early ontogeny.

For example, quinpirole

caused a dose-dependent increase in locomotor activity
from PD 10 to PD 20; however, quinpirole-induced

locomotion subsequently declined at PD 30 and PD 60 (Van
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Hartesveldt, Meyer, & Potter, 1994).

In addition, SKF

38393-induced grooming and quinpirole-induced vertical

movement was observed at PD 21, but not at PD 3 or at PD
10 (Moody & Spear, 1992).

In summary, there are some

drug-induced ontogenetic effects, but research typically

shows that dopamine agonists and antagonists cause
qualitatively similar effects across the life-span.
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CHAPTER FIVE

EFFECTS OF PARTIAL DOPAMINE D2-LIKE AGONISTS
ON UNLEARNED BEHAVIOR

Systemic and Central Administration of Partial D2-Like
Agonists in Adult Rats
Partial D2-like agonists have both agonistic and

antagonistic effects on behavior (Spealman,

1995); however,

the preponderance of studies indicates that partial D2like agonists have antagonistic effects (Kikuchi, Tottori,
Uwahodo, Hirose, Miwa, Oshiro, SPMorita, 1995; for a

review, see Pulvirenti & Koob, 1994).

For example,

partial D2-like agonists (e.g., SDZ 208-911, SDZ 208-912,

OPC-14597,

(-)-3-PPP, and terguride) reduce amphetamine-

or apomorphine-induced locomotion and stereotyped behavior

(Clark et al., 1991; Kikuchi et al., 1995) .

Further,

apomorphine-induced hyperlocomotion, cataplexy, and
stereotyped behavior were blocked by the partial D2-like

agonist terguride (Kohler & Herbster, 1987).

Consistent

with its actions as an antagonist drug, microinjecting the
partial D2-like agonist (-)-3-PPP into the ventral
striatum, but not the dorsal striatum, decreased
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exploratory behavior in adult rats (Svensson & Ahlenius,

1983) .
Partial D2-like agonists seldom exhibit agonistic

effects when tested on behavioral paradigms.

However, one

example of an agonistic effect is provided by Arnt and
Perregaard (1987), because co-administration of B-HR 920

(a partial D2-like agonist) and SKF 38393

(a direct Dl-

like agonist) induced contralateral turning in
hemitransectioned-rats.

A few other examples of

agonistic-like effects are available, as the stimulus

effects of cocaine were increased by administering SDZ

208-911 to monkeys (Spealman, 1995).
et al.

In addition, Orsini

(2001) demonstrated the agonistic effects of

terguride by measuring saccharin-reinforced responding in
dopamine-depleted rats.

Normally, rats exhibit suppressed

responding for a natural reward (e.g., saccharin) when
they are in a state of low dopaminergic tone; however,

terguride exhibited agonistic properties by reversing this
effect.

In conclusion, partial D2-like agonists exhibit

both agonistic and antagonistic properties in adult rats.
Partial D2-like agonists typically act as antagonists in
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behavioral models but, in a few circumstances, partial D2like agonists have been shown to act like agonists.

Systemic Administration of Partial D2-Like Agonists in
Preweanling Rats

Partial D2-like agonists have both agonistic and

antagonistic behavioral effects in adult animals; however,
it is not known whether a similar pattern of effects is

evident in younger animals.

In studies conducted by

McDougall and colleagues (2005),'antagonistic effects of
partial D2-like agonist were found.

More specifically,

terguride was able to block NPA-, amphetamine-, and

cocaine-induced locomotor activity (McDougall, Hernandez,
Reichel,

2003).

& Farley, 2005; Sibole, Matea, Krall, & McDougall,

Interestingly, terguride also reduced locomotor

activity under the- saline condition as well.

This

indicates that terguride acts as an antagonist under

conditions of normal and enhanced dopaminergic tone in

preweanling animals.
As with terguride, the partial D2-like agonist (-)-3-

PPP induces antagonistic effects in preweanling rats.

More specifically, young rats (PD 11 and PD 20) exhibited

increased locomotor activity when injected with the full
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D2-like agonist (+)-3-PPP, but no effect was found when
they were injected with the partial D2-like agonist (-)-3-

PPP (Arnt, 1983).

In addition, when (-)-3-PPP was given

to rats at PD 11, PD 20, or PD 30, it antagonized
amphetamine-induced hyperactivity, however this effect was
not observed after treatment with (+)-3-PPP (Arnt, 1983).
Interestingly, the preponderance of studies have

shown that partial D2-like agonists have pronounced

antagonistic effects during the preweanling period (Arnt,
1983; McDougall et al., 2005; Sibole et al., 2003);

however, evidence of agonistic properties has not been

found.

McDougall et al.

(2005) used either an escalating

regimen of amphetamine or AMPT (a tyrosine hydroxylase
inhibitor) to induce states of low dopaminergic tone in

preweanling rats.

Rats were then given an injection of

saline, terguride, or NPA.

The full D2-like agonist NPA

enhanced locomotor activity in states of low dopaminergic

tone, whereas terguride did not stimulate locomotor
activity.

These behavioral results suggest that partial

D2-like agonists do not exhibit agonistic properties

during the preweanling period.
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While a few studies have shown that partial D2-like

agonists act like agonists in adult rats, comparable
studies have not shown agonistic actions in young animals

under a state of low dopaminergic tone.

There are a

number of possible explanations for this apparent

ontogenetic difference.

First, during amphetamine

withdrawal (a state of low dopaminergic tone), terguride

may not have induced agonistic effects because of a
More specifically,

substantial receptor reserve.

reducing dopaminergic tone is believed to "create a
receptor reserve where none had existed before"

(Meller et

al., 1987), and it should cause partial D2-like agonists
to exhibit agonistic effects.

However, it is possible

that preweanling rats have a very large receptor reserve,

thus even under a state of low dopaminergic tone terguride

was not able to produce agonist-like effects (McDougall et
al., 2005).
Second, terguride may not act like an agonist under a

state of low dopaminergic tone due to a presumed
immaturity of D2-like receptors.

According to Carlsson

(1983), the conformation of a receptor changes depending

on intrinsic activity (see also Clark et al., 1985;
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Drukarch & Stoof, 1990).

Theoretically, partial D2-like

agonists should act as agonists under low dopaminergic
tone (i.e., low intrinsic activity), because of

conformational changes in the D2-like receptor.

It is

possible that during the preweanling period these

conformational changes may not occur in the same manner in
adulthood.

Lastly, terguride may not have elicited agonistic

effects under a state of low dopaminergic tone because of
paradigmatic considerations.

McDougall et al.

Specifically, in the

(2005) study, a state of low dopaminergic

tone was presumably induced by AMPT or an escalating

regimen of amphetamine.

It is possible that neither of

these manipulations was sufficient to induce a state of

low dopaminergic tone in preweanling rats.

Therefore, it

remains possible that partial D2-like agonists will

exhibit agonistic properties in preweanling rats if
manipulations cause a more intense or prolonged reduction

in dopamine levels.

In light of these considerations, the

use of non-behavioral paradigms (i.e., measuring
autoreceptor mediated changes in dopamine synthesis) may
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be necessary to determine whether partial D2-like agonists

exhibit agonistic properties during the preweanling period
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CHAPTER SIX
DOPAMINE SYNTHESIS

Effects of Full Dopamine D2-Like Drugs
on Dopaminergic Synthesis
Dopamine synthesis is frequently defined as the
accumulation of L-DOPA after treatment with the aromatic

amino acid decarboxylase inhibitor, 3hydroxybenzylhydrazine hydrochloride (NSD 1015)(Cooper et

al. , 2003) .

One of the primary ways to determine the

agonistic and antagonistic effects of dopaminergic drugs
is to assess drug-induced changes in dopamine synthesis.
For example, when the D2-like agonist, N-0437, is given to
NSD 1015-treated rats, DOPA accumulation declines.

Similarly, dorsal striatal DOPA accumulation is reduced
when NSD 1015-treated rats are injected with amphetamine,

NPA, or apomorphine (Argiolas, Melis, Fadda, Serra, &
Gessa, 1982) .

Conversely, the D2-like antagonist

haloperidol causes a dose-dependent increase in DOPA

accumulation in NSD 1015-treated rats (Svensson, Eriksson,
Sc Carlsson, 1993) .

It is also of interest to determine the effects of
dopamine agonists and antagonists during a state of low
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dopaminergic tone.

To that end, reserpine, which is a

dopamine depleting agent (Ahlenius,•Hillegaart, &
Wijkstrom, 1991; Argiolas et al., 1982; Guldberg & Broch,
1971; Roth & Stone, 1968), is frequently used to create a

state of low dopaminergic tone (Svensson, Ekman, Piercey,
Hoffman, Lum, & Carlsson, 1991).

After acute

administration of reserpine, the D2-like agonist

quinpirole causes a dose-dependent decrease in dorsal

striatal DOPA accumulation, whereas haloperidol or
sulpiride (D2-like antagonists) increase DOPA accumulation

(Ahlenius et al., 1991; Argiolas et al., 1982; Svensson et
al., 1991).

This phenomenon is regulated by dopamine

autoreceptors in the dorsal striatum (Murrin & Roth, 1987)
Autoreceptor-mediated effects can also be examined by
measuring DOPA accumulation after treatment with the

impulse inhibitor y-butyrolactone (GBL)
& Roth, 1981; Kehr, 1984).

(Bannon, Michaud,

Not surprisingly, GBL

dramatically increases DOPA accumulation in the dorsal
striatum (Bannon et al., 1981; Kehr, 1984).

Apomorphine

reverses this GBL-induced increase in DOPA accumulation,
whereas haloperidol accelerates dopamine synthesis in the

striatum (Bannon et al., 1981).
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Thus, full agonists and

antagonists differentially affect GBL-induced DOPA
accumulation.

Effects of Partial Dopamine D2-Like Agonists
on Dopaminergic Synthesis

Partial D2-like agonists bind to autoreceptors, but
(Lahti,

their intrinsic activity is less than full agonists

Mutin, Cochrane, Tepper, Dijkstra, Wikstrom, & Tamminga,
1996; Lahti, Weiler, Corey, Lahti, Carlsson, & Tamminga,

1997).

In a state of high dopaminergic tone, partial D2-

like agonists typically act like antagonist drugs.

For

example, the partial D2-like agonist (-)-3-PPP causes a

dose-dependent decline in DOPA accumulation in NSD 1015-

treated rats; however, a dose-dependent increase in DOPA
accumulation was observed after administration of the full

agonist ( + )-3-PPP (Clark, Salah, & Galloway, 1991) .

Similarly, SDZ 208-911 and terguride dose-dependently
reduced striatal DOPA accumulation (after treatment with
NSD 1015) by 80%, whereas SDZ 208-912 only produced a 32%
reduction (Svensson et al., 1991).

SDZ 208-911 and

terguride partially reversed (by approximately 50%) the

GBL-induced increase in striatal DOPA accumulation, but
SDZ 208-912, which is a weaker partial agonist, was
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inactive under the same conditions.

In summary, evidence

suggests that partial D2-like agonists function like

antagonists during states of high dopaminergic tone.
Pretreatment with the dopamine depleting agent
reserpine creates a state of low dopaminergic tone: a
situation where partial D2-like agonists function like

agonist drugs. For example, terguride and SDZ 208-911,
like quinpirole, reduce DOPA accumulation (after injection

of NSD 1015) in the dorsal striatum by approximately 80%

(Svensson et al., 1991).

D2-like antagonists, on the

other hand, increase striatal DOPA accumulation in
reserpinized rats (Argiolas et al., 1982) .

The impulse inhibitor GBL also induces a functional
state of low dopaminergic tone.

Not surprisingly, GBL-

induced DOPA accumulation is inhibited by both full (e.g.,

quinpirole) and partial (e.g., terguride, SDZ 208-911,
OPC-14597, and OPC-4392) D2-like agonists

(Ahlenius et al.,

1991; Clark, Hjorth, & Carlsson, 1984; Kikuchi et al. 1995;
Svensson et al., 1991).

These effects of partial D2-like

agonists are subsequently blocked by the D2-like
antagonist haloperidol (Svensson, 1991) .
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CHAPTER SEVEN

SUMMARY AND HYPOTHESES

General Summary and Hypotheses

Partial D2-like agonists exhibit either agonistic or
antagonistic properties in adult rats depending on the
state of dopaminergic tone (for a review, see Clark et al.,
1985).

More specifically, in adult rats, partial D2-like

agonists have antagonistic effects under a state of high

dopaminergic tone, and agonistic effects under a state of

low dopaminergic tone (for a review, see Pulvirenti & Koob,
1994) .
A somewhat different pattern of effects are observed

in early ontogeny.

In preweanli'ng rats, partial D2-like

agonists function as antagonists in states of high
.1

dopaminergic tone (Arnt, 1988; McDougall et al., 2005;
Sibole et al., 2003). In states of low dopaminergic tone,
however, partial D2-like agonists continue to function
like antagonist drugs (McDougall et al., 2005).

words, terguride consistently functioned like an
antagonist drug in behavioral paradigms using the
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In other

preweanling rat: effects that were apparent during states

of low or high dopaminergic tone.
In addition to employing behavioral paradigms, the

effects of partial D2-like agonists have been examined by
measuring autoreceptor-mediated changes in dopamine

synthesis (Iyengar, Hausler, Kim, Marient, Alter, & Wood,

1989; Lahti et al., 1996; Li, Ichikawa, Dai, & Meltzer,
2004).

In states of high dopaminergic tone (no reserpine

or GBL treatment), partial D2-like agonists exhibit
antagonistic (haloperidol-like) effects in adult rats

(Ahlenius et al., 1991; Argiolas et al., 1982; Svensson et
al., 1991). On the other hand, in states of low
dopaminergic tone (i.e., after reserpine or GBL treatment)
partial D2-like agonists exhibit agonistic (quinpirolelike) effects in adults.

In summary, in both behavioral and neurochemical
paradigms involving adult rats, partial D2-like agonists
function as antagonists during states of high dopaminergic

tone, but function as agonists in states of low
dopaminergic tone.

In contrast, available behavioral

evidence suggests that partial D2-like agonists function

exclusively as antagonists during the preweanling period
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(Arnt, 1983; McDougall et al., 2005; Sibole et al., 2003).
However, no ontogenetic studies have directly examined the

effects of partial D2-like agonists using neurochemical
paradigms.
The purpose of this thesis, therefore, was to

determine the effects of partial D2-like agonists on
dorsal striatal dopamine synthesis during the preweanling

period.

To this end, preweanling rats were treated with

saline or reserpine (either acutely or repeatedly) in

Experiment 1.

On the test day, the saline- or reserpine-

pretreated rats were injected with the partial D2-like

agonist terguride, the full D2-like agonist quinpirole, or
the full D2-like antagonist haloperidol.

injected with NSD 1015.

Rats were then

It was hypothesized that

terguride would induce antagonistic (haloperidol-like)

effects in a state of high dopaminergic tone (after saline

treatment), while showing agonistic (quinpirole-like)
effects in a state of low dopaminergic tone (after
repeated reserpine treatment). •

It was also hypothesized

that terguride would induce antagonistic effects after

acute reserpine treatment.
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The rationale for these hypotheses was based on the

intensity and longevity of dopamine depletion.
et al.

McDougall

(2005) showed that short-term or mild dopamine

depletion was insufficient to cause terguride to exhibit

agonist-like properties.

Therefore, I hypothesized that

prolonged dopamine depletion (i.e., after repeated

reserpine treatment) would induce a state of dopaminergic
tone sufficiently low to cause agonistic effects in
terguride-treated rats.

Because acute administration of

AMPT did not induce agonist-like effects in terguridetreated rats (see McDougall et al., 2005), it was

hypothesized that acute reserpine treatment would also be
insufficient to induce a state of low dopaminergic tone.

If the data do not support these hypotheses (i.e., if
terguride causes antagonist-like effects in Experiment 1),

then it is possible that preweanling rats have a smaller

receptor reserve than adult rats.

Alternatively,

preweanling rats may not show adult-like changes in
receptor conformation after dopamine depletion.
Experiment 2 was designed to examine the effects of

terguride using GBL.

The GBL model is a technique used to

induce a state of low dopaminergic tone by inhibiting
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nerve impulse flow (Walters & Roth, 1976) .

In adult rats,

GBL-induced DOPA accumulation is inhibited by both partial
and full D2-like agonists (Ahlenius et al., 1991; Clark et
al., 1984; Kikuchi et al. 1995; Svensson et al., 1991).
Importantly, the effects of partial D2-like agonists on

GBL-induced DOPA accumulation have not been assessed in
preweanling rats.

Therefore, preweanling rats were

injected with terguride, quinpirole, or haloperidol.

Rats

were subsequently injected with GBL prior to NSD 1015

treatment.

It was predicted that terguride would exhibit

agonistic (quinpirole-like) properties (i.e., reversing
GBL-induced DOPA accumulation).

This pattern of results

would indicate that partial D2-like agonists cause

agonistic effects during’ a state of low dopaminergic tone.
Lastly, Experiment 3 was designed to examine whether
haloperidol would block terguride's effects using the GBL
model.

Preweanling rats were injected with saline or

haloperidol, followed by an injection of saline, terguride,
or quinpirole.
by NSD 1015.

Rats were then treated with GBL followed

It was predicted that haloperidol would

block the ability of terguride and quinpirole to reverse

GBL-induced DOPA accumulation.
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This pattern of results

would indicate that:

1) the actions of terguride are

mediated by dopamine receptors; and 2) terguride and

quinpirole are functioning like agonists, while
haloperidol is functioning like an antagonist.
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CHAPTER EIGHT
GENERAL METHODS

Subj ects
Subjects were 240 male and female Sprague-Dawley rats

(Charles River), born and raised in the animal colony at

California State University, San Bernardino.

All litters

were culled to 10 by PD 3 and the pups remained with the

dam throughout testing.

Before the pretreatment period,

rats were randomly assigned to treatment groups. All

subjects were given food and water ad lib.

The colony

room was maintained at 21 - 23°C, and was on a 12 light/12
dark cycle.

All subjects were treated in accordance with

the ethical principles as outlined by the American

Psychological Association (1992).

Drugs

Terguride, haloperidol, quinpirole, NSD 1015 (3hydroxybenzylhydrazine hydrochloride), and GBL (y-

butyrolactone) were dissolved in saline.

Reserpine was

dissolved in a minimal amount of glacial acetic acid and

diluted with saline.

All drugs were purchased from Sigma
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(St. Louis, MO) and were injected intraperitoneally (ip)
at a volume of 5 ml/kg.

Apparatus

A high performance liquid chromatograph (582 pump and
a MD-150 column; ESA, Chelmsford, MA) with an

electrochemical detector (Coulochem II; ESA) was used to
measure DOPA accumulation.

The mobile phase consisted of

75 mM NaH2PO4, 1.4 mM 1-octane sulfonic acid, 10 mM EDTA,
I
and 10% acetonitrile [(pH 3.1) MD-TM Mobile Phase; ESA]

and was pumped at a rate of 0.5 ml/min.

Assay Procedures
Frozen dorsal striatal sections were sonicated in 10

volumes of 0.1 N HC1O4 and centrifuged at 20,000 x g for 3 0

min at 4°C.

The supernatant was then filtered through a

0.22 pirn centrifugation unit at 2,000 x g for 5 min at 4°C.

Twenty microliters of the resulting extract was assayed
for DOPA accumulation using high performance liquid

chromatography.
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Statistical Analysis

Analysis of variance (ANOVA) was used to analyze

neurochemical data.

Litter effects were controlled by

assigning no more than one subject per litter to a
particular treatment group.

Post-hoc comparison of the

neurochemical data was conducted using Tukey tests (p
< .05) .

I
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CHAPTER NINE
EXPERIMENT ONE

Overview

Experiment 1 examined whether terguride has
agonistic-like effects during states of low dopaminergic

tone and antagonistic-like effects during states of high
dopaminergic tone.

To that end, dopamine synthesis (i.e.,

DOPA accumulation after treatment with NSD 1015) was

measured in saline- or reserpine-treated preweanling rats
(acute or repeated treatment).

Rats in the acute

condition received one reserpine injection and rats in the

repeated condition received reserpine treatment for five

consecutive days (see procedure for more details).

In

control animals, it was predicted that terguride, like
haloperidol, would enhance dopamine synthesis.

Conversely,

terguride was hypothesized to act like quinpirole in
reserpinized rats (i.e., dopamine synthesis would/be

depressed).

It was also predicted that terguride would

inhibit dopamine synthesis in the repeated reserpine
condition but not in the acute reserpine condition group.
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Procedures
Preweanling rats (n = 144) were randomly divided into
three conditions: control, repeated reserpine, and acute

reserpine.

Rats in the control condition received saline

injections on PD 16 - PD 20; rats in the repeated
reserpine condition received reserpine (1 mg/kg, ip)

injections on PD 16 - PD 20; rats in the acute reserpine

condition received a single injection of reserpine (1
mg/kg, ip) on PD 20.

After 24 hr, all rats were injected

with the full D2-like antagonist haloperidol (0.5 mg/kg,
ip), the partial D2-like agonist terguride (0.1, 0.4, or

1.6 mg/kg, ip), the full D2-like agonist quinpirole (0.5
mg/kg, ip), or saline (n = 8 per group). After an

additional 30 min, rats were injected with NSD 1015 (100
mg/kg, ip).

Rats were then sacrificed 30 min later and

their dorsal striata were stored at -70°C until time of

assay (see Table 1).

Statistics
A 3 x 6 (pretreatment condition x post treatment)

ANOVA was used to determine whether DOPA levels differed
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Table 1. Injection paradigm of Experiment 1.
I

Condition

PD

First
Injection

Time

Second
Inj ection

Time

Repeated
Reserpine

16-20

Terguride

3 0 min

NSD 1015

3 0 min

Sacrifice

Saline

16-20

Quinpirole

3 0 min

NSD 1015

3 0 min

Sacrifice

Acute
Reserpine

20

Haloperidol

3 0 min

NSD 1015

3 0 min

Sacrifice

Saline

3 0 min

NSD 1015

3 0 min

Sacrifice

I

Rats were pretreafed with' reserpine or saline. On the test
day, rats were injected with terguride, quinpirole,
haloperidol, or saline. All rats were then injected with
NSD 1015.
'
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according to treatment group.

DOPA accumulation after NSD

1015 treatment was used as an index of dopamine synthesis.

Results

Pretreatment condition interacted with post treatment
group to affect striatal DOPA accumulation [F (10,90) =

20.19, p < 0.001]

(see Fig. 3).

In the vehicle-

pretreatment condition, the partial D2-like agonist
terguride had antagonist-like effects in vehicle-

pretreat ed rats (under high dopaminergic tone), because
both haloperidol and terguride caused a significant
increase in DOPA accumulation when compared to the control

group [F (5, 30) = 63.77, p < 0.001].

In addition,

haloperidol caused a greater increase in DOPA accumulation
than did terguride.

More specifically, haloperidol caused

a 313% increase in DOPA accumulation, while terguride
caused a 165% increase over control values.

On the other

hand, the D2-like agonist quinpirole significantly reduced

DOPA accumulation in comparison to saline controls.

In the reserpine-pretreated conditions (acute and
repeated), terguride caused a quinpirole-like effect.

Both terguride and quinpirole significantly reduced DOPA
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Results from Experiment 1. Significantly
from saline controls from the same pretreatment
(p < 0.05). bSignificantly different from
groups from the same pretreatment condition (p <
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accumulation relative to the saline controls [acute

reserpine: F (5, 30) = 79.72, p < 0.0001; repeated

reserpine: F (5, 30) = 27.86, p < 0.001].

More

specifically, all doses of terguride (0.4, 0.8, and
1.6mg/kg) significantly decreased DOPA accumulation in the
acute reserpine condition; however, only 1.6 mg/kg

terguride decreased DOPA accumulation in the repeated

reserpine condition. Haloperidol significantly increased
DOPA accumulation in both the acute and repeated reserpine
conditions.
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CHAPTER TEN

EXPERIMENT TWO

Overview
Experiment 2 examined whether terguride caused

agonistic-like effects using the GBL model.

GBL creates a

state of low dopaminergic tone by inhibiting impulse flow;

therefore, the effects of partial and full dopamine-acting
drugs on DOPA accumulation was measured in GBL-treated

rats.

It was predicted that terguride would exhibit

agonist-like (quinpirole-like) effects under a state of ■
low dopaminergic tone (in GBL-treated animals). In other
words, terguride, like quinpirole and opposite to

haloperidol, was expected to reverse GBL-induced DOPA
accumulation.

Procedures
On PD 21, preweanling rats (n = 48) were injected

with the full D2-like antagonist haloperidol (0.5 mg/kg,
ip), the partial D2-like agonist terguride (0.1, 0.4, or

1.6 mg/kg, ip), the full D2-like agonist quinpirole (0.5
mg/kg, ip), or saline.

After 25 min later, they were
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injected with GBL (625 mg/kg, ip).

After an additional 5

min, an injection of NSD 1015 (100 mg/kg, ip) was given.

Rats were sacrificed 30 min later and their dorsal striata
were stored at -70°C until time of assay (see Table 2).
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Table 2. Injection paradigm for Experiment 2.

First
Inj ection

Time

Second
Inj ection

Time

Third
Injection

Time

Terguride

25 min

GBL

5 min

NSD 1015

3 0 min

Sacrifice

Quinpirole

25 min

GBL

5 min

NSD 1015

3 0 min

Sacrifice

Haloperidol

25 min

GBL

5 min

NSD 1015

3 0 min

Sacrifice

Saline

25 min

GBL

5 min

NSD 1015

3 0 min

Sacrifice

Rats were first injected with terguride, quinpirole,
haloperidol, or saline. They were then given an injection
GBL prior to NSD 1015.
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Statistics

A one-way (treatment group) ANOVA was used to

determine whether DOPA levels differed according to
treatment group.

DOPA accumulation after NSD 1015

treatment was used as an index of dopamine synthesis.

Results
As expected, the partial D2-like agonist terguride

(0.1, 0.2, 0.8, and 1.6 mg/kg) and the full D2-like
agonist quinpirole significantly reduced DOPA accumulation
(see Fig. 4)

[F (7, 40) = 16.27, p < 0.001].

Interestingly, quinpirole caused a greater reduction in

DOPA accumulation than terguride.

On the other hand,

haloperidol significantly increased DOPA accumulation
relative to saline controls.
Surprisingly there were no dose-dependent effects

observed among the terguride groups.

More specifically,

DOPA accumulation did not vary across the extended dose
range (0.1-1.6 mg/kg) of terguride.

This result may be

due to a "ceiling effect" of the partial D2-like agonist,
with 0.1 mg/kg terguride producing a maximal effect on
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DOPA Accumulation

HAL

Terguride

QUIN

Figure 4. Results from Experiment 2. aSignificantly
different from saline controls (p < 0.05). bSignificantly
different from terguride groups (p < 0.05).
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DOPA accumulation.

This possibility seems unlikely,

because terguride has previously been shown to produce
dose-dependent effects across the same range of doses used
in the present experiment (Clark et al., 1991).

In the

latter study, however, terguride's effects were assessed
in a behavioral paradigm using adult rats.
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CHAPTER ELEVEN

EXPERIMENT THREE

Overview

Experiment 3 examined the combined effects of

terguride and haloperidol using the GBL model.
Preweanling rats were pretreated with both GBL and NSD
1015.

Rats were then injected with saline or haloperidol

followed by a later injection of saline, terguride, or

quinpirole.

It was predicted that terguride and

quinpirole would reverse GBL-induced DOPA accumulation,

and that this effect would be blocked by haloperidol.
This pattern of results would indicate that the actions of

terguride are mediated by dopamine receptors.

It would

also indicate that terguride and quinpirole were
exhibiting agonistic properties during a state of low

dopaminergic tone, while haloperidol was acting as an
antagonist.

Procedures

On PD 21, preweanling rats (n = 48) were injected

with saline or the full D2-like antagonist haloperidol
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(0.5 mg/kg, ip) followed, 30 min later, by an injection of

the partial D2-like agonist terguride (dose to be
determined in Experiment 2), the full D2-like agonist

quinpirole (0.5 mg/kg, ip), or saline.

After an

additional 25 min, rats were injected with GBL (625 mg/kg,
ip), followed, 5 min later, by an injection of NSD 1015

(100 mg/kg, ip).

Rats were sacrificed 30 min later and

their dorsal striata were stored at -70°C until time of

assay (see Table 3).

Statistics
A 2 x 3

(pretreatment condition x post treatment)

ANOVA was used to determine whether DOPA levels differed
according to treatment group.

DOPA accumulation after NSD

1015 treatment was used as an index of dopamine synthesis.

Results
As expected, both terguride (0.8 and 1.6 mg/kg) and

quinpirole significantly reduced DOPA accumulation when
compared to control values [F (4, 50) = 7.66, p < 0.001]
(see Fig. 5), with quinpirole's effects being more robust.
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Table 3. Injection paradigm for Experiment 3.

First
Injection

Time

Second
Injection

Time

Third
Injection

Time

Fourth
Injection

Time

Haloperidol

30
min

Terguride

25
min

GBL

5
min

NSD 1015

30
min

Sacrifice

Saline

30
min

Quinpirole

25
min

GBL

5
min

NSD 1015

30
min

Sacrifice

Saline

25
min

GBL

5
min

NSD 1015

30
min

Sacrifice

On the test day (PD 21), rats were first injected with
haloperidol or saline. After the fist drug
administration, they were injected with terguride,
quinpirole, or saline. They were then injected with GBL
and NSD 1015.
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SAL

Figure 5.
different
different
different
identical

Terguride

QUIN

Results from Experiment 3. aSignificantly
from saline controls (p < 0.05). bSignificantly
from terguride groups (p < 0.05). cSignificantly
from saline-pretreated rats receiving the
dose of terguride and quinpirole (p < 0.05).
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Haloperidol significantly reversed quinpirole-induced DOPA
accumulation, however, this effect was only observed for

one of the terguride groups (0.4 mg/kg).

More

specifically, haloperidol reversed the DOPA accumulation

caused by 0.4 mg/kg terguride, but haloperidol did not

significantly reverse the effects of the higher terguride
doses (0.8 or 1.6 mg/kg).
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CHAPTER TWELVE
DISCUSSION

Effects of Terguride After Acute and
Repeated Reserpine Treatment
on Dopamine Synthesis in
Preweanling Rats
The purpose of present study was to examine the

neurochemical effects of terguride under high or low
dopaminergic tone using preweanling rats.

In adult rats,

partial D2-like agonists function as antagonists during

states of high dopaminergic tone, but function as agonists
in states of low dopaminergic tone using both behavioral
and neurochemical paradigms.

In contrast, available

behavioral evidence suggests that partial D2-like agonists
function exclusively as antagonists during the preweanling

period (Arnt, 1983; McDougall et al., 2005; Sibole et al.,
2003); however, no ontogenetic studies have directly

examined the effects of partial D2-like agonists using

neurochemical paradigms.

In the present study, therefore, dopamine synthesis
(i.e., DOPA accumulation after treatment with NSD 1015)

was measured in saline- or reserpine-pretreated rats
(acute or repeated treatment) (Experiment 1) .
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Rats in the ■

acute condition received one reserpine injection on PD 20,

while rats in the repeated condition received reserpine

treatment for five consecutive days (PD 16 - PD 20).

It

was predicted that terguride would depress dopamine

synthesis after repeated reserpine treatment (low
dopaminergic tone).

Conversely, it was hypothesized that

terguride would enhance dopamine synthesis in control
animals (high dopaminergic tone). It was also predicted
that terguride would not affect dopamine synthesis in the
acute reserpine condition.

These hypotheses were partially supported by the

results.

As hypothesized, under a state of high

dopaminergic tone (i.e., in the vehicle-pretreated
condition), the partial D2-like agonist terguride had

antagonist-like effects.

Like haloperidol, terguride

caused significant increases in DOPA accumulation when
compared to the control group.

In addition, haloperidol

caused a greater increase in DOPA accumulation than

terguride.

In a state of low dopaminergic tone (i.e.,

after acute or repeated reserpine treatment), terguride

caused the opposite effect (i.e., terguride had agonist
like actions).

Like the full D2-like agonist quinpirole,
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terguride reduced DOPA accumulation after acute or

repeated reserpine treatment.

The reduction in DOPA

accumulation was more robust in the quinpirole group than

the terguride groups.

That terguride causes agonist-like effects after

repeated reserpine treatment was expected, but I
originally hypothesized that terguride would still act
like an antagonist after acute reserpine treatment.

The

basis for the latter hypothesis was that short-term
dopamine depletion using AMPT did not cause agonistic

behavioral effects in terguride-treated rats (McDougall et
al., 2005).

Therefore, I hypothesized that repeated, but

not acute, administration of reserpine would produce a

state where terguride induced agonistic neurochemical
effects.

However, the results from the present study

showed that acute administration of reserpine was

sufficient to create a state of low dopaminergic tone that
would allow terguride to exhibit agonistic effects.

Perhaps, the ability of AMPT and reserpine to induce a
state of low dopaminergic tone differs in young animals.
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Effects of Terguride on DOPA
Accumulation in Preweanling
Rats Using the GBL Model
In addition to using reserpine to induce a state of

low dopaminergic tone, GBL was used to examine the effects
of autoreceptor-mediated changes in neurotransmitter

synthesis.

GBL creates a state of low dopaminergic tone

by inhibiting impulse flow; therefore, the effects of
partial and full dopamine-acting drugs on DOPA
accumulation was measured in GBL-treated rats.

In

Experiment 2, it was predicted that terguride would
exhibit agonistic (quinpirole-like) effects in GBL-treated
animals. In Experiment 3, it was hypothesized that
terguride would reverse GBL-induced DOPA accumulation, and
that this effect would be blocked by haloperidol.

This

pattern of results would indicate that the actions of

terguride were mediated by dopamine receptors.
As predicted, terguride (0.1, 0.2, 0.8, and 1.6
mg/kg), like quinpirole, significantly reversed GBLinduced DOPA accumulation.

Surprisingly, there were no

dose-dependent effects observed among the terguride groups
Although they were not significantly different from each

other, there was a dose-dependent trend (i.e., an increase
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in DOPA accumulation) up to 0.4 mg/kg and then a transient
decline above 0.4 mg/kg.

This transient effect may be due

to the unique properties of partial D2-like agonists.

As

indicated before, partial D2-like agonists have high
affinity and low intrinsic activity at presynaptic sites

(Carlson, 1983).

Therefore, when a partial D2-like

agonist was injected at a low dose, it showed "true"
partial agonist effects (showing high affinity but low

intrinsic effect), however, when it was given at a higher
dose, it showed more full agonist-like effects

(quinpirole-like effects).

In addition, this

nonsignificant dose-dependent effect may also be due to a

"ceiling effect" of the partial D2-like agonist.

As

indicated before, since there were no significant

differences among the terguride groups, it may be possible
that 0.1 mg/kg terguride was sufficient to induce a
maximal effect.

Once again, quinpirole had a more robust

effect on dopamine accumulation than terguride did.

Haloperidol significantly increased DOPA accumulation

relative to the control values (see Fig. 4).

Haloperidol

also significantly reversed the quinpirole-induced
reductions in DOPA accumulation.
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Interestingly, this

effect was only observed in one of the terguride groups

(0.4 mg/kg).

More specifically, haloperidol only blocked

the effects of 0.4 mg/kg terguride, while the effects of

0.8 or 1.6 mg/kg terguride were not attenuated by the
antagoni st drug.
The inability of haloperidol to block the effects of

0.8 or 1.6 mg/kg terguride suggests that some of
terguride's effects may be mediated by other receptor
systems.

Unlike adult rats, preweanling rats have a DI

autoreceptor that modulates dopamine synthesis (Teicher,
Gallitano, Gelbard, Marsh, Booth, & Baldessarini, 1991).
Teicher and colleagues (1991) examined the ontogeny of DI
autoreceptor-mediated effects by comparing young and adult

rats using the GBL model.

They found that Dl-like

agonists, SKF 38393 and CY 208243, significantly reduced
the GBL-induced increase in DOPA accumulation in young (PD

15-16) but not adult rats.

This transient expression of

Dl-like autoreceptors suggests that both DI- and D2-like
autoreceptors are present and functional in developing
brains.

In the present study, therefore, it is possible

that terguride may have been affecting DOPA accumulation
by binding to both D2 and DI autoreceptors.
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If true, it

might explain why haloperidol did not fully antagonize
terguride's effects on DOPA accumulation, because
haloperidol has almost no affinity for DI receptors.

GBL Model
GBL is used to induce a state of low dopaminergic

tone by inhibiting nerve impulse flow (Walters & Roth,
1976).

When impulse flow is inhibited, release of

dopamine at the terminals is disrupted, resulting in a
decrease in the synaptic levels of dopamine.

Decreased

levels of synaptic dopamine result in disinhibition of

autoreceptors, which leads to increased DOPA accumulation
(Wolf & Roth, 1987).

In other words, blocking impulse

flow increases dopamine synthesis by modulating
presynaptic receptors (Walters & Roth, 1976).

This GBL-

induced DOPA accumulation is capable of being altered by
dopamine-acting drugs.

For example, amphetamine, which

increases dopamine levels, causes a significant reduction

in GBL-induced DOPA accumulation (Walters & Roth, 1976).
Conversely, haloperidol significantly increases GBL-

induced DOPA accumulation when compared to controls.

addition, haloperidol reverses the amphetamine-induced
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In

reduction in GBL-induced DOPA accumulation (Walters & Roth,
1976) .

In the present thesis, preweanling rats exhibited
adult-like neurochemical effects.

Specifically,

quinpirole (a full D2-like agonist) caused a significant
reduction in GBL-induced DOPA accumulation, while

haloperidol (a D2-like antagonist) enhanced DOPA

accumulation.

These results provide additional evidence

that autoreceptors are functionally mature during the late

preweanling period.

Autoreceptors in Preweanling Rats

Early studies suggested that the autoreceptors of
young animals were not functional during the early
adolescent period (Shalaby & Spear, 1980; Hedner &

Lundborg, 1985).

However, results from the present study

indicate that autoreceptors function in an adult-like
manner during the late preweanling period (i.e., on PD 21).

This conclusion is consistent with a study conducted by
Andersen et al.

(1997) using full D2-like agonists.

Andersen et al.

(1997) measured DOPA accumulation in the

striatum, nucleus accumbens, and prefrontal cortex after
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rats were treated with (+)-7-OH-DPAT, GBL, and NSD 1015 on

PD 10, PD 15, PD 20, PD 30, and PD 40.

The full D2-like

agonist (+)-7-OH-DPAT inhibited striatal GBL-induced DOPA
accumulation at all ages.

These results support our

contention that autoreceptors are present and functional

during the late preweanling period.
Interestingly, Andersen et al.

(1997) also found that

GBL-induced DOPA accumulation was inhibited in the
prefrontal cortex after (+)-7-OH-DPAT treatment in 10-,
15-, 20-, and 30-day-old rats.

Although the present

thesis only tested the effects of terguride in the
striatum, it would be interesting to determine whether a
partial D2-like agonist affects DOPA accumulation

similarly in the prefrontal cortex of preweanling rats.

In any event, the present study was the first to show that
a partial D2-like agonist would induce adult-like

neurochemical effects during the preweanling period.

Conformational Theory
In the present study, partial agonists had opposite

neurochemical effects depending on the state of
dopaminergic tone.

According to Carlsson (1983), the
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conformation of a receptor changes depending on intrinsic

activity (see also Clark et al., 1985; Drukarch & Stoof,
1990).

More specifically, responsiveness of a receptor to

different agonist drugs varies depending on the state of

the receptor.

The intrinsic activity and previous

occupancy of the receptor plays a very critical role.

For

example, after high receptor occupancy, partial D2-like

agonists act a's antagonists; whereas after low receptor

occupancy, partial D2-like agonists act as agonists.

These changes in receptor occupancy slowly induce a
conformational change in the receptor, thus influencing

the responsiveness of the receptor.

In other words, the

adaptability of receptor molecules alters the

responsiveness to partial D2-like agonists.
In the present study, the partial D2-like agonist

terguride induced agonistic effects under low receptor
occupancy (low dopaminergic tone) and antagonistic effects

under high receptor occupancy (high dopaminergic tone).

This is an important finding because it has not been
previously shown that partial agonists will induce this
pattern of effects in preweanling rats.
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For such effects

to occur, dopamine autoreceptors must be functioning in an
adult-like manner by PD 21.

Receptor Reserve Theory
An alternative explanation for the actions of partial

D2-like agonists is provided by the receptor reserve

theory.

This theory suggests that partial D2-like

agonists only exhibit agonistic actions in the presence of

a large receptor reserve (Meller et al., 1987).

More

specifically, because partial D2-like agonists possess low

intrinsic efficacies, they cannot stimulate a receptor-

mediated response in the absence of a substantial receptor
reserve.

For example, when a full agonist (NPA) and

partial agonist ((-)3-PPP) are administered under high

receptor reserve conditions, both drugs elicit a maximal
tissue response that is indistinguishable from one another
Thus, with a large receptor reserve, partial D2-like

agonists act like agonists (e.g., decrease DOPA

accumulation).

On the other hand, partial D2-like

agonists act like antagonists (e.g., increase DOPA

accumulation) when there is little or no receptor reserve.
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In the present study, a partial D2-like agonist

elicited agonist-like and antagonist-like effects under

low and high dopaminergic tone, respectively.

These

results suggest that both acute and repeated reserpine
treatment produced a large receptor reserve.

Conversely,

little or no receptor reserve was present after vehicle

treatment.
When considered together, I believe that the receptor
reserve theory better explains the results of the present

study.

This conclusion - is largely drawn from results of

the reserpine experiment (Experiment 1).

According to

Carlsson (1983), changes in receptor occupancy are only

capable of slowly inducing a conformational change in the

receptor.

However, terguride caused similar effects in

rats treated acutely or repeatedly with reserpine.

Thus,

reserpine must either be capable of inducing more rapid

conformational changes than Carlsson suggests or the
conformational theory cannot fully explain the present
results.

73

Clinical Aspects of Partial D2-Like Agonists

Before partial D2-like agonists were commercially

available to the public, D2-like antagonists were used to
treat schizophrenia, motor dysfunction, and drug addiction

(for a review, see Wetzel & Benkert, 1992).

However, due

to their severe side effects (e.g., vomiting, diarrhea,
dizziness, drowsiness, and motor dysfunction), researchers

have been searching for drugs that do not possess these
types of extrapyramidal side effects.
Recently, partial DA agonists (e.g., aripiprazole,

preclamol, terguride, SDZ 208-911, and SDZ 208-912) have

drawn much clinical attention because of their unique
ability to "normalize" dopamine functioning, without

causing extrapyramidal side effects (Carson, Kane, Ali,
Dunber, & Ingenito, 2000; Pulvirenti et al., 1998).

Partial D2-like agonists alleviate drug withdrawal

symptoms, decrease motor dysfunction, and reduce symptoms
of schizophrenia and delusional disorders (for a review,

see Benkert, Muller-Siecheneder, & Wetzel, 1995).

For

example, in a study using schizophrenic subjects,

terguride reduced both positive and negative psychotic
behaviors (Filip, Marsalek, Halkova, & Karen, 1991).
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In

addition, motor dysfunction was reduced after taking the
same drug.

More specifically, when terguride was given to

patients with restless leg syndrome, symptomology was
significantly reduced, and their restless leg syndrome

symptoms were improved without major side effects (Sonka,
Pretl, & Kranda, 2003).

Therefore, the unique

neurochemical properties of■ partial agonists (i.e., the
ability to induce agonistic and antagonistic effects) have

proven to be of great therapeutic benefit.

Conclusion
In preweanling rats, partial D2-like agonists act as
agonists under low dopaminergic tone and as antagonists

under high dopaminergic tone.

This conclusion is based on

experiments using the dopamine depleting agent reserpine
and the impulse flow inhibitor GBL.

Both of these drugs

were able to create a state of low dopaminergic tone thus
causing terguride to exhibit agonist (quinpirole-like)

properties.

Results from the present thesis also indicate that

dopamine autoreceptors are present and functional by PD 21

It remains unknown whether the responsiveness of partial
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agonist drugs is altered by previous receptor occupancy
(conformational theory) or changes in receptor reserve.

Future investigation is necessary to determine which

theory accurately explains the actions of partial D2-like
agonists during the preweanling period.
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